glp 1 contraindications pancreatitis What are the for starting Glucagon-like peptide-1 (GLP-1) receptor agonists? Non-insulin injectable antidiabetic drugs -
Description
10.1016/j.drudis.2016.01.013 Drug Discov
Han B, Liu JL, Huan Y, Li P, Wu Q, Lin ZY, et al
After 26 weeks of treatment discontinuation, the trajectory of weight regain leveled off, which implied that significant weight regain might happen at the first 6 months after discontinuation of AOMs
104 Cotadutide by AstraZeneca and efinopegdutide by Merck Sharp & Dohme are other GLP-1R/GCGR dual agonists
NAD is a coenzyme, not a peptide
